We are deeply concerned about the tragic and shocking events happening in Ukraine. We utterly condemn the military action and the harm and suffering it’s causing to people in Ukraine and beyond.

As a global HIV company, our priority is to work closely with GSK and our partners to do everything we can to support our colleagues and people living with HIV in Ukraine and across this region.

Through our partnerships with the UN-backed Medicines Patent Pool and Aurobindo, we have voluntary licensing agreements in place to enable generic manufacturers to supply low cost dolutegravir-based regimens to Ukraine as well as other countries in the area.

We are actively working with our existing partners to determine the best way to support people living with HIV in Ukraine and the surrounding area, including those displaced by the war, with continued access to care.

We are making available significant donations of anti-retroviral medicines to WHO, National HIV/AIDS programmes and NGO partners to support children and adults living with HIV who have been impacted by the conflict. This includes offering support for National HIV/AIDS programmes in neighbouring EU countries who are receiving refugees and for an NGO supporting displaced people currently in Russia who cannot return to their home country and cannot access HIV treatment in Russia. We are also working with WHO to finalise a donation of medicine for children living with HIV in Ukraine.

We are additionally making over £600,000 in emergency funds available to our existing charitable partners through our Positive Action programme to support continued delivery of care to people living with HIV impacted by the conflict.

With GSK, we are actively supporting initial relief efforts through partners on the ground, such as Save the Children, and have contributed to GSK's £3 million donation to the Red Cross’s Ukraine Crisis work which is working to fund food, water, first aid, medicines, warm clothes and shelter for refugees.

We’ll review our response as the situation evolves to ensure we care for our colleagues and that we are continuing to do all that we can to support our partners and people living with HIV, wherever they are.

We fully support the measures being taken by governments across the world to respond to these tragic events, including the implementation of sanctions.

Media contacts

For our corporate press office, email: Rachel Jaikaran

OR call +44 7823 523 755

For US-specific media enquiries, email: Audrey Abernathy

OR call +1 919 605 4521


Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.